Epidemiology of COVID-19 in Jiangxi, China: A retrospective observational study.

ABSTRACT: To analyze the epidemiological characteristics of coronavirus disease 2019 (COVID-19) in Jiangxi Province, China, from January 21 to April 9, 2020.COVID-19 epidemic information was obtained from the official websites of the Jiangxi Provincial Health Committee, Hubei Provincial Health Committee, and National Health Commission of the People's Republic of China. ArcGIS 10.0 was used to draw a map of the spatial distribution of the cases.On January 21, 2020, the first COVID-19 confirmed case in Jiangxi was reported. By January 27, COVID-19 had spread rapidly to all cities in Jiangxi. The outbreak peaked on February 3, with a daily incidence of 85 cases. The last indigenous case reported on February 27. From January 21 to April 9, a total of 937 confirmed cases of COVID-19 were reported, with a cumulative incidence of 2.02/100,000. Of those, 936 patients (99.89%) were cured, and 1 (0.11%) died due to COVID-19. The COVID-19 epidemic trend in Jiangxi was basically consistent with the national epidemic trend (except Hubei). Throughout the epidemic prevention and control phase, Jiangxi province has taken targeted prevention and control measures based on the severity of the spread of COVID-19.The COVID-19 epidemic in Jiangxi was widespread and developed rapidly. In less than 1 month, the epidemic situation was effectively controlled, and the epidemic situation shifted to a low-level distribution state. All these proved that the COVID-19 prevention and control strategies and measures adopted by Jiangxi Province were right, positive and effective.

Spontaneous polarization induced electrostatic charge in washable electret composite fabrics for reusable air-filtering application

The performance of disposable face masks in blocking pathogenic microbes mainly relies on the ability of melt-blown fabrics to electrostatically adsorb air droplets. While their easy invalidity in electrostatic effect highly limits their use recyclability, leading to a heavy burden on the surrounding environment due to their decomposing difficulty. Thus, it is urgent to develop reusable air filtration fabrics. In this work, we report a washable electret air-filtering fabrics with negligible cytotoxicity by combining spontaneous polarizing photochromic molecule with electrospinning electret technology. The electrostatic charge and filtration efficiency of the composite fabrics were highly improved compared to the commercial polypropylene melt-blown fabrics. Moreover, due to its electrostatic charge induced by self-polarization, the photochromic Spiropyran(SP)/polystyrene(PS) electret fabrics can maintain high filtration performance (over 95%) towards PM0.3 particles and low air flow resistance (<343.2 Pa) even after 5 times of washing (by 75% ethanol)/drying cycles. The combination of self-polarization photochromic molecule and electret material with negligible toxicity would create high-performance reusable air filtering fabrics, thereby SP/PS composite fabrics have a potential application in eco-friendly recyclable air purification and isolation and protection of pathogenic microbes.

HIV infection and risk of COVID-19 mortality: a meta-analysis

Background: This meta-analysis aimed to estimate the association of human immunodeficiency virus (HIV) infection and risk of coronavirus disease 2019 (COVID-19) mortality.

HIV infection and risk of COVID-19 mortality: A meta-analysis.

BACKGROUND: This meta-analysis aimed to estimate the association of human immunodeficiency virus (HIV) infection and risk of coronavirus disease 2019 (COVID-19) mortality. METHODS: We systematically retrieved articles published on HIV infection and risk of COVID-19 mortality through PubMed, EMBase, China National Knowledge Infrastructure, WanFang, and Chongqing VIP databases using a predefined search strategy from December 1, 2019 to January 31, 2021. Newcastle-Ottawa Scale (NOS) was used to assess the quality of the included studies. Cochran Q test and I2 statistics were quantified to measure heterogeneity. Odds ratio (OR) and 95% confidence intervals (CI) were computed and displayed in the form of forest plots. Subgroup analysis was performed to explore the source of heterogeneity. Funnel plot, Begg test, and Egger test were used to assess potential publication bias. Stata software version 11.0 was used to analyze all the statistical data. RESULTS: We included 10 studies with 18,122,370 COVID-19 patients, of whom 41,113 were with HIV infection and 18,081,257 were without HIV infection. The pooled overall results suggested that people living with HIV infection had a higher risk of mortality from COVID-19 than those without HIV infection (OR = 1.252, 95% CI 1.027-1.524). Subgroup analysis showed that people living with HIV infection had a higher risk of COVID-19 mortality than those without HIV infection in the United States (OR = 1.520, 95% CI 1.252-1.845) and in South Africa (OR = 1.122, 95% CI 1.032-1.220); however, no significant association was found in the United Kingdom (OR = 0.878, 95% CI 0.657-1.174). CONCLUSION: Patients with HIV infection should be the emphasis population to prevent the risk of mortality during the clinical treatment of COVID-19 patients.

Estimation of Incubation Period and Serial Interval for SARS-CoV-2 in Jiangxi, China, and an Updated Meta-Analysis.

INTRODUCTION: This paper aims to estimate the incubation period and serial intervals for SARS-CoV-2 based on confirmed cases in Jiangxi Province of China and meta-analysis method. METHODOLOGY: Distributions of incubation period and serial interval of Jiangxi epidemic data were fitted by "fitdistrplus" package of R software, and the meta-analysis was conducted by "meta" package of R software. RESULTS: Based on the epidemic data of Jiangxi, we found the median days of incubation period and serial interval were 5.9 days [IQR: 3.8 - 8.6] and 5.7 days [IQR: 3.6 - 8.3], respectively. The median days of the infectivity period at pre-symptomatic was 1.7 days [IQR: 1.1 - 2.4]. The meta-analysis based on 64 papers showed the pooled means of the incubation period and serial interval were 6.25 days (95% CrI: 5.75 - 6.75) and 5.15 days (95% CrI: 4.73 - 5.57), respectively. CONCLUSIONS: Our results contribute to a better understanding of COVID-19 and provide useful parameters for modelling the dynamics of disease transmission. The serial interval is shorter than the incubation period, which indicates that the patients are infectious at pre-symptomatic period, and isolation of detected cases alone is likely to be difficult to halt the spread of SARS-CoV-2.

Sequence-specific and multiplex detection of COVID-19 virus (SARS-CoV-2) using proofreading enzyme-mediated probe cleavage coupled with isothermal amplification.

The outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been challenging human health worldwide. Loop-mediated isothermal amplification (LAMP) has been promptly applied to the detection of SARS-CoV-2 owing to its high amplification efficacy and less requirement of the thermal cycler. However, the vast majority of these LAMP-based assays depend on the non-specific detection of LAMP products, which can not discern the undesirable amplificons, likely to yield unreliable results. Herein, a sequence-specific LAMP assay was reported to detect SARS-CoV-2 using proofreading enzyme-mediated probe cleavage (named Proofman), which could realize real-time and visual detection without uncapping. This assay, introducing a proofreading enzyme and the fluorogenic probe to reverse-transcription LAMP (RT-Proofman-LAMP), can specifically detect the SARS-CoV-2 RNA with a detection limit of 100 copies. In addition to the real-time analysis, the assay is capable of endpoint visualization under a transilluminator within 50 min, providing a convenient reporting manner under the setting of point-of-care testing (POCT). In combination with different fluorophores, the one-pot multiplex assay was successfully achieved to detect multiple targets of SARS-CoV-2 and inner control simultaneously. In summary, the development of RT-Proofman-LAMP offers a versatile and highly-specific method for fast field screening and laboratory testing of SARS-CoV-2, making it a promising platform in COVID-19 diagnosis.

Development of a Simple In Vitro Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA-Dependent RNA Polymerase.

Nucleotide analogs targeting viral RNA polymerase have been proved to be an effective strategy for antiviral treatment and are promising antiviral drugs to combat the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. In this study, we developed a robust in vitro nonradioactive primer extension assay to quantitatively evaluate the efficiency of incorporation of nucleotide analogs by SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). Our results show that many nucleotide analogs can be incorporated into RNA by SARS-CoV-2 RdRp and that the incorporation of some of them leads to chain termination. The discrimination values of nucleotide analogs over those of natural nucleotides were measured to evaluate the incorporation efficiency of nucleotide analog by SARS-CoV-2 RdRp. In agreement with the data published in the literature, we found that the incorporation efficiency of remdesivir-TP is higher than that of ATP and incorporation of remdesivir-TP caused delayed chain termination, which can be overcome by higher concentrations of the next nucleotide to be incorporated. Our data also showed that the delayed chain termination pattern caused by remdesivir-TP incorporation is different for different template sequences. Multiple incorporations of remdesivir-TP caused chain termination under our assay conditions. Incorporation of sofosbuvir-TP is very low, suggesting that sofosbuvir may not be very effective in treating SARS-CoV-2 infection. As a comparison, 2'-C-methyl-GTP can be incorporated into RNA efficiently, and the derivative of 2'-C-methyl-GTP may have therapeutic application in treating SARS-CoV-2 infection. This report provides a simple screening method that should be useful for evaluating nucleotide-based drugs targeting SARS-CoV-2 RdRp and for studying the mechanism of action of selected nucleotide analogs.